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ACTIVE SURVEILLANCE: BACKGROUND 
AND RATIONALE
Active surveillance (AS) is a management strategy 
in a superselect group of  low-risk prostate cancer (PCa) 
patients involving close monitoring of the course of disease 
with the expectation to intervene if cancer progresses. By 
delaying intervention for indolent tumors and treating 
only when more clinically-significant PCa is detected, AS 
minimizes overtreatment. Compared with watchful waiting, 
which involves monitoring the course of  PCa with the 
expectation of delivering palliative therapy for development 
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of symptoms, change in exam, or prostate specific antigen 
(PSA) that suggests symptoms are imminent, AS is mainly 
applicable to younger men with seemingly indolent cancer, 
with the goal of deferring treatment and its potential side 
effects (Table 1). Because such patients have a longer life 
expectancy, they should be followed closely, and treatment 
should start promptly before the cancer progresses so as not 
to miss the chance for cure.
Such a unique concept of  treatment is based on 
concerns about overdiagnosis and overtreatment related 
to the increased diagnosis of  PCa due to the widespread 
use of  PSA for early detection or screening. The debate 
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regarding the need to diagnose and treat every man with 
PCa is originated from: the high prevalence of  PCa on 
prostate autopsy and the discrepancy between incidence and 
mortality rates of PCa [1-4]. The controversy regarding the 
value of PSA screening for early detection of PCa [3-9] was 
emphasized by the Goteborg study, a subset of the European 
Randomized Study for Screening of Prostate Cancer (ERSPC) 
[10]. Although the study showed a 40% absolute cumulative 
risk reduction of PCa mortality (compared to ERSPC 20% 
and PLCO [Prostate, Lung, Colorectal, and Ovarian Cancer 
Screening Trial] 0%), 293 men needed to obtain screening 
visits and 12 needed to be diagnosed in order to prevent 
one PCa death. Moreover, the estimated probability of 
overtreatment ranged from 23% to 42% of all screen-detected 
cancers [11], and cancer detection was responsible for up to 
12.3 years of lead-time bias [12].
CURRENT AS PROTOCOLS
In the 2015 National Comprehensive Cancer Network 
(NCCN) guidelines, AS is recommended in men with very-
low-risk PCa (T1c, Gleason score [GS]≤6, PSA<10 ng/mL, 
fewer than three biopsy cores positive, ≤50% cancer in any 
core, PSA density [PSAD]<0.15 ng/mL/g) and life expectancy 
≤20 years. The European Association of Urology guidelines 
[13] are similar: clinically confined PCa (T1–T2), GS≤6, three 
or fewer biopsies involved with cancer, ≤50% of each biopsy 
involved with cancer, and PSA<10 ng/mL.
The NCCN recommendation for follow-up schedule 
during AS includes PSA no more often than every 6 months 
unless clinically indicated, digital rectal examination (DRE) 
no more often than every 12 months unless clinically 
indicated, and repeat prostate biopsy considered annually 
to assess for disease progression (Biopsy should be repeated 
within 6 months of diagnosis if initial biopsy was <10 cores 
or assessment discordant; for example, palpable tumor 
contralateral to the side of positive biopsy). A repeat prostate 
biopsy is indicated when DRE change or PSA increase, 
although neither parameter is very reliable for detecting 
PCa progression.
The panel recommends starting intervention when GS 4 
or 5 cancer is found upon repeat prostate biopsy, when PCa 
is found in a greater number of prostate biopsies, or when 
PCa occupies a greater extent of  the prostate biopsy, as 
these findings are regarded as cancer progression. Different 
criteria have been applied to define cancer progression [14], 
although most groups used the following criteria: PSA-
doubling time (DT) with a cutoff ranging between ≤2 and ≤4 
years, GS progression to ≥7 at rebiopsy (at intervals ranging 
from 1 to 4 years), PSA progression >10 ng/mL, although the 
role of PSA-DT in identifying the need for intervention has 
recently been challenged [15-17].
AS: ADVANTAGES AND DISADVANTAGES
The advantages of  AS include: (1) avoiding the side 
effects of  definitive therapy that may not be necessary; 
(2) maintaining quality of  life and normal activities; (3) 
minimizing the risk of unnecessary treatment for small, 
indolent cancers; and (4) low initial costs. The disadvantages 
of AS include: (1) possibility of missing an opportunity for 
cure; (2) possibility of progression or metastasis of the cancer 
before treatment; (3) increased difficulty in the treatment 
of  more aggressive cancer with greater side effects; (4) 
increased difficulty of the nerve-sparing technique during 
radical prostatectomy; (5) increased anxiety of living with 
untreated cancer; (6) need to examine and undergo frequent 
prostate biopsies; (7) uncertain long-term natural history of 
untreated PCa; and (8) undetermined timing and value of 
periodic imaging studies.
“INSIGNIFICANT PROSTATE CANCER”: 
APPLICATIONS
Patients with insignificant PCa might be ideal AS 
candidates, considering its indolent nature. Currently, there 
are no biological markers to clearly differentiate tumors 
that will progress or be indolent. Hence, statistical models 
Table 1. Active surveillance versus watchful waiting
Active surveillance Watchful waiting
Treatment intent Curative Palliative
Follow-up Predefined schedule Patient-specific
Assessment/markers used DRE, PSA, rebiopsy, optional MRI Not predefined
Life-expectancy >10 y <10 y
Aim Minimize treatment-related toxicity without compromising survival Minimize treatment-related toxicity
Comments Only for low-risk patients Can apply to patients at all stages
DRE, digital rectal examination; PSA, prostate-specific antigen; MRI, magnetic resonance imaging.
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have been developed to predict tumor aggressiveness. Epstein 
et al. [18,19] suggested a model using preoperative clinical 
and pathologic features that can predict “insignificant PCa” 
(tumor volume<0.2 mL, GS<7, and organ-confined tumor). 
The preoperative parameters used in this model include 
no GS 4 or 5 in biopsy pathology, PSAD≤0.1 ng/mL/g, less 
than three involved biopsy cores (with a minimum of six 
total cores being obtained), no core with >50% involvement 
or PSAD of  0.1 to 0.15 ng/mL/g, and cancer <3 mm in 
only one prostate biopsy core specimen. Stamey et al. [20] 
proposed that tumors <0.5 mL could probably be regarded 
as insignificant with respect to the long DT. Recently, 
Wolters et al. [21] challenged this widely accepted definition 
of insignificant PCa. The authors reported that clinically 
insignificant PCa might include index GS 6 and pT2 disease 
with index volume ≤1.3 mL and total volume ≤2.5 mL.
An appropriate, reliable definition of  “insignificant 
PCa” is crucial for the following reasons. If the definition 
is too stringent, a significant proportion of  insignificant 
PCa patients would be ineligible for AS and become the 
object of unnecessary intervention [22]. Conversely, without 
a stringent definition, treatment of  low-risk PCa could 
probably be suboptimal, especially in this era of  robotic 
surgery and focal therapies with relatively low morbidities.
However, there are numerous studies reporting the risks 
of unfavorable pathological features such as upgrading of 
GS and pathologic upstaging in prostatectomy specimens 
from patients who were initially regarded as having 
insignificant PCa according to preoperative Epstein criteria; 
the frequency of  such features ranged from 16% to 42% 
[23]. The risk of GS upgrading was approximately 30% in a 
previous meta-analysis [24]. Other series [25,26] have shown 
that up to 8% of cancers that qualified as being insignificant 
according to the Epstein criteria were not organ-confined in 
the postoperative pathologic reports.
These findings suggested the need for caution against 
using this protocol as it is, and many variations regarding 
this definition have been suggested (reviewed by Bastian et 
al. [27]).
VARIOUS AS PROTOCOLS
Several contemporary AS protocols are shown in Table 
2 from Johns Hopkins Medical Institution (JHMI) [28], 
Memorial Sloan-Kettering Cancer Center (MSKCC) [29], 
University of  California at San Francisco (UCSF) [30], 
Prostate Cancer Research International: Active Surveillance 
(PRIAS) [31], University of Miami (UM) [32], and One Asian 
protocol [33].
DISEASE RECLASSIFICATION
During AS, some of patients in the favorable-risk group 
are at risk, owing to pre-existing higher-risk disease that was 
not obvious at initial diagnosis or to disease progression over 
time. These patients can be detected by close monitoring 
such as serial measurement of PSA value or prostate biopsy 
and reclassified into the higher-risk group.
The Toronto group, JHMI group, and UCSF group 
recently reported the follow-up results of their AS patients 
(Table 3). Approximately one-third of these patients were 
reclassified as higher-risk and treated over time. The PCa 
mortality was quite low in an intermediate time frame 
(5–10 years). As for the active treatments during AS, 
radical prostatectomy or radiation therapy +/− androgen 
deprivation therapy was performed. In the Toronto group, 
the 5-year biochemical recurrence-free survival rates in the 
surgery and radiation treatment groups were only 62% and 
43%, respectively. However, in the Johns Hopkins group 
[31], the 5-year biochemical recurrence-free survival rates 
were 96% and 75% for the surgery and radiation treatment 
groups, respectively. In addition, Ha et al. [36] reported their 
early experience with AS. They concluded PSA-DT was not 
associated with cancer progression, suggesting the need to 
Table 2. Contemporary active surveillance protocols
Institution Clinical stage Gleason score PSA (ng/mL) PSAD
No. of positive  
cores
Single core  
involvement (%)
JHMI [28] T1c ≤6 -   ≤0.15 ≤2 ≤50
MSKCC [29] T1c–T2a ≤6 ≤10 - ≤3 ≤50
UCSF [30] T1c–T2 ≤6 ≤10 - ≤33% (at least 6) ≤50
PRIAS [31] T1c–T2 ≤6 ≤10 ≤0.2 ≤2 -
UM [32] T1c–T2 ≤6 ≤15 - ≤2 ≤20
Kakehi [33] T1c ≤6 ≤20 - ≤2 ≤50
PSA, prostate specific antigen; PSAD, PSA density; JHMI, Johns Hopkins Medical Institution; MSKCC, Memorial Sloan-Kettering Cancer Center; 
UCSF, University of California at San Francisco; PRIAS, Prostate Cancer Research International: Active Surveillance; UM, University of Miami.
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perform regular prostate biopsy. They also emphasized that 
application of AS strategy to Korean patients should carry 
very careful considerations.
AS PROTOCOL IN AN ASIAN POPULATION
Considering the clinicopathological differences in PCa 
between Western and Korean populations [37], there have 
been concerns about the validity of Western AS protocols 
in Korean PCa patients [38,39]. Kim et al. [38] evaluated 
several Western AS protocols by applying these protocols 
to their RP series and compared the pre- and postoperative 
pathologic characteristics. Of 1,006 patients, GS upgrading 
occurred in 41.6% to 50.6%, extracapsular extension in 4.1% 
to 8.5%, seminal vesicle invasion in 0.5% to 1.6%, pathologic 
upstaging in 4.5% to 9.3%, and misclassification in 44.5% 
to 54.8% of patients. These data suggest the possibility of 
underestimation of  Korean PCa by current Western AS 
protocols.
Several studies have compared the current Western AS 
protocols to determine their reliability [22,40-44]. Lee et al. [44] 
analyzed several contemporary AS protocols (from JHMI, 
UCSF, MSKCC, UM, and PRIAS) with regard to sensitivity, 
specificity, and accuracy in order to determine the validity 
of these criteria for Korean PCa patients. According to their 
analysis, the PRIAS protocol was most appropriate among 
five Western protocol for Korean men to determine AS 
candidates.
In 2013, Lim et al. [45] suggested new AS criteria for 
Korean patients: cT1–cT2, GS≤6, PSA≤10 ng/mL, ≤1 positive 
biopsy core, and ≤50% core involvement. KaKehi et al. [33] 
developed AS protocols for Japanese patients: T1c, PSA≤20 
ng/mL, ≤2 positive cores, GS≤6, and ≤50% cancer involvement 
in any of the positive cores. Goto et al. [43] reported that 
the JHMI and PRIAS criteria were most helpful for use in 
Japanese Pca patients. In addition, Jin et al. [46] reported the 
strong correlation between PSAD and GS upgrading after 
RP, emphasizing the use of PSAD for choosing ideal AS 
candidates. According to their analysis, the optimal PSAD 
cutoff value was 0.13 ng/mL2.
AS PROTOCOL: USE OF MAGNETIC RES-
ONANCE IMAGING
In an effort to enhance accuracy during selection of 
AS candidates, there have been several reports on the use 
of  magnetic resonance imaging (MRI) for prediction of 
insignificant PCa. Some authors [47,48] have reported that 
the use of apparent diffusion coefficient from diffusion-
weighted magnetic resonance imaging (DW-MRI) might 
be helpful for choosing AS candidates. Early experience 
supports the use of multiparametric MRI in biopsy protocols 
for better risk-stratif ication of  patients on AS [49,50]. 
Recently, Park et al. [51] reported associations between 
adverse pathological features in PCa patients eligible for 
AS and clear tumor identiﬁcation on 3.0-T multiparametric 
MRI (combination of T2WI, DCEI, and DWI). Lee et al. [52] 
reported preliminary results that a simple measurement 
of the diameter of a suspicious tumor lesion on DW-MRI 
improves the prediction of insignificant PCa. According to 
their study, the possibility of insignificant Pca increased 
when tumor diameter was smaller than 1 cm.
CONCLUSIONS
Determination of  AS candidates should be based on 
Table 3. Reports on disease reclassification during active surveillance
Variable University of Toronto [34] JHMI [28] UCSF [35]
Median age (y) 70 66 63
No. of patients 450 769 513
Median follow-up (mo) 6.8 2.7 3.6
Conversion to intervention (%) 30 33 24
Median time to treatment (y) - 2.2 3.5
Overall survival 68 98 98
Cancer-specific survival 97 100 100
Primary reason for treatment
   PSA increase 14a - 26b
   GS change 8 14 38
   Anxiety 3 9 8
JHMI, Johns Hopkins Medical Institution; UCSF, University of California at San Francisco; PSA, prostate specific antigen; GS, Gleason score.
a:PSA doubling time <3 y. b:PSA velocity >0.75 ng/mL/y.
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careful individualized weighing of numerous factors: life 
expectancy, general health condition, disease characteristics, 
potential side effects of treatment, and patient preference. 
The timing of intervention should be based on change in 
PSA or pathology or clinical disease progression. Patients 
with clinically localized PCa who are candidates for 
definitive treatment but choose AS should undergo regular 
follow-up. In addition, follow-up should be more rigorous 
in younger men than in older men due to the higher life 
expectancy in the former group.
Currently, NCCN panels emphasize the urgent need 
for further clinical studies regarding the criteria for 
recommending AS, the criteria for reclassif ication on 
AS, and the schedule for AS, especially as it is associated 
with prostate biopsy, which unfortunately come within 
an increasing burden. Literatures report that up to 7% of 
men undergoing prostate biopsy will experience side effects 
[7], those with urinary tract infection are often quinolone-
resistant [53], and surgery may become difficult after 
multiple prostate biopsies [54].
Considering the racial differences in behavior of PCa 
between Western and Asian populations, more stringent 
AS protocols for Asian patients should be established from 
additional, well-designed, large clinical studies.
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